INCREASED INCIDENCE OF INSULIN-DEPENDENT DIABETES MELLITUS IN PEDIATRIC RENAL TRANSPLANT PATIENTS RECEIVING TACROLIMUS (FK506)
- 15 March 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 65 (5) , 617-619
- https://doi.org/10.1097/00007890-199803150-00003
Abstract
Background. Use of tacrolimus (FK506), a potent immunosuppressive agent, has been reported to have a 10-20% incidence of insulin-dependent diabetes mellitus (IDDM) in adults, but the incidence of IDDM in pediatric renal transplant recipients treated with this agent is unknown. In this article, we report our single-center experience with FK506-induced IDDM in children. Methods. Five consecutive living related donor pediatric renal transplants were reviewed retrospectively. Results. All five patients developed IDDM lasting longer than 6 months. Mean follow-up time was 18.6 months. Conclusions. Pediatric patients may be at high risk for developing FK506-induced IDDM.Keywords
This publication has 7 references indexed in Scilit:
- Initial experience with FK506 (tacrolimus) in pediatric renal transplant recipientsJournal of Pediatric Surgery, 1997
- A COMPARISON OF TACROLIMUS (FK506) AND CYCLOSPORINE FOR IMMUNOSUPPRESSION AFTER CADAVERIC RENAL TRANSPLANTATION1Transplantation, 1997
- Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving prograf and cellcept in combination therapyTransplantation Proceedings, 1997
- DIABETOGENICITY OF FK506 VERSUS CYCLOSPORINE IN LIVER TRANSPLANT RECIPIENTSTransplantation, 1994
- Comparison of FK-506 and cyclosporine regimens in pediatric renal transplantationPediatric Nephrology, 1994
- CONVERSION FROM CYCLOSPORINE TO FK506 FOR SALVAGE OF IMMUNOCOMPROMISED PEDIATRIC LIVER ALLOGRAFTS EFFICACY, TOXICITY, AND DOSE REGIMEN IN 23 CHILDRENTransplantation, 1994
- Pediatric Renal Transplantation under FK-506 ImmunosuppressionJournal of Urology, 1992